---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-23-000112"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2023-09-01T23:59:59+00:00"
generated_at: "2026-06-11T00:23:55.543544+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio subsidiary to enforce settlement as Sorrento fails to pay judgments

## Summary
- Sorrento failed to pay judgments held by NantCell and NANTibody by August 31, 2023 deadline.
- NantCell and NANTibody to deliver certification of non-payment by September 6, triggering settlement terms.
- Upon certification, mutual release of claims, release of judgments, and Sorrento relinquishes NANTibody interests.
- Sorrento forfeits rights to payments from antibody license including royalties from PD-L1 t-haNK NK cell therapy.

## SEC filing metadata
- accession: 0001326110-23-000112
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2023-09-01T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000112/0001326110-23-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000112/ibrx-20230831.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-23-000112
- JSON: https://secwatch.observer/filing/0001326110-23-000112.json
- Plain text: https://secwatch.observer/filing/0001326110-23-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.